Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective

INTRODUCTION: Ranibizumab and aflibercept are anti-vascular endothelial growth factor agents licensed for the treatment of visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). The aim of this study was to estimate, from a UK healthcare payer’s perspective, the co...

Descripción completa

Detalles Bibliográficos
Autores principales: Adedokun, Lola, Burke, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735224/
https://www.ncbi.nlm.nih.gov/pubmed/26747252
http://dx.doi.org/10.1007/s12325-015-0279-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735224/
https://www.ncbi.nlm.nih.gov/pubmed/26747252
http://dx.doi.org/10.1007/s12325-015-0279-0

Ejemplares similares